Valuation: Inventiva

Market Cap 914M 1.05B 844M 775M 1.47B 101B 1.49B 10.07B 3.95B 49.19B 3.93B 3.84B 170B P/E 2026 *
-5.3x
P/E 2027 * -5.35x
Enterprise Value 697M 798M 643M 591M 1.12B 76.75B 1.14B 7.68B 3.01B 37.51B 3B 2.93B 129B EV / Sales 2026 *
129x
EV / Sales 2027 * 1.52x
Free-Float
89.08%
Yield 2026 *
-
Yield 2027 * -
1 day-0.13%
1 week+3.62%
Current month+20.03%
1 month+23.29%
3 months-18.46%
6 months-32.31%
Current year-2.03%
1 week 3.57
Extreme 3.57
3.94
1 month 2.88
Extreme 2.88
4.04
Current year 2.88
Extreme 2.88
6.2
1 year 2.64
Extreme 2.645
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
13.18
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 2025-09-30
Director of Finance/CFO 59 2026-04-21
Chief Tech/Sci/R&D Officer 56 2025-07-29
Director TitleAgeSince
Director/Board Member 75 2017-01-31
Director/Board Member 63 2019-05-26
Director/Board Member 52 2024-04-30
Date Insider Type Main position Quantity % Market Cap.
01-09Others

General Counsel

25,000 0.0131%
01-09Others

Chief Operating Officer

25,000 0.0131%
01-09Others

Executive/Senior Manager

50,000 0.0262%
Change 5-day change 1-year change 3-year change Capi.($)
-0.13%+3.62%+40.04%+7.06% 1.05B
+3.13%+13.95%+64.21%+94.35% 57.82B
-0.67%-6.43%+53.42%+70.38% 53.71B
-0.27%-5.77%+6.75%+433.06% 23.8B
+1.76%-1.65%-16.86%-15.01% 23.26B
-0.56%+6.10%+44.56%-3.75% 20.7B
-1.00%-2.69%+33.52%-30.08% 17.81B
+10.00%-4.30%+208.33%+370.99% 16.9B
-2.61%+10.00%+47.02%+699.54% 16.36B
-0.39%-1.00%+26.08%+186.49% 13.96B
Average +0.93%+1.57%+50.71%+181.30% 24.54B
Weighted average by Cap. +1.10%+1.35%+51.21%+158.55%

Financials

2026 *2027 *
Net sales 5.42M 6.2M 5M 4.59M 8.7M 596M 8.85M 59.66M 23.41M 291M 23.27M 22.76M 1B 118M 135M 109M 100M 190M 13.01B 193M 1.3B 511M 6.36B 508M 496M 21.91B
Net income -146M -167M -134M -124M -234M -16.04B -238M -1.6B -630M -7.84B -626M -612M -27.01B -86.23M -98.63M -79.54M -73.12M -139M -9.49B -141M -950M -373M -4.64B -370M -362M -15.99B
Net Debt -217M -248M -200M -184M -349M -23.88B -355M -2.39B -938M -11.67B -932M -912M -40.23B -734M -840M -678M -623M -1.18B -80.83B -1.2B -8.09B -3.17B -39.51B -3.15B -3.09B -136B
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
73
Date Price Change Volume
26-07-16 3.865 -0.13% 18,529
26-07-15 €3.870 +1.31% 246,378
26-07-14 €3.820 +2.00% 357,604
26-07-13 €3.745 +0.40% 243,336
26-07-10 €3.730 0.00% 451,050
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.870EUR
Average target price
9.634EUR
Spread / Average Target
+148.95%

Quarterly revenue - Rate of surprise